Editas IPO Will Test Investment Crispness For CRISPR Gene Editing
This article was originally published in Scrip
By filing for an initial public offering on NASDAQ the genomics company Editas Medicine Inc. hopes to cash in on rising awareness of gene editing's power and the simplicity promised from the so-called CRISPR technique.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.